Status:
UNKNOWN
The Effect of RadiaAce Gel in the Prevention and Treatment of Radiation Dermatitis in Breast Cancer Patients
Lead Sponsor:
AceTech
Conditions:
Breast Cancer
Radiation Dermatitis
Eligibility:
FEMALE
18-120 years
Phase:
NA
Brief Summary
Radiation dermatitis (RD) is one of the most common side effects of Radiation therapy (RT) and 95% of patients receiving RT may experience some form of radiation dermatitis. A wide variety of topical...
Eligibility Criteria
Inclusion
- Female patients
- Age \> 18
- Patients with histologically-confirmed diagnosis of breast cancer
- Patients after breast lumpectomy and that scheduled to receive radiotherapy
- Patients to receive minimum of 40.05 Gy to primary field
- Must be able to comply with treatment schedule
- Study-specific signed informed consent prior to randomization
Exclusion
- Inflammatory or connective tissue disorders of the skin
- Mental incompetence, including psychological or addictive disorders which would preclude completion of questionnaires
- Previous radiation therapy to the breast
- Tumour involvement of the skin
- Rash, ulceration or open wound in treatment field
- Known skin allergy or sensitivity to Aloe Vera or Biafine
- Current lactation
- Pregnancy
- Any other reason that, in the opinion of the investigator, prevents the subject from
Key Trial Info
Start Date :
July 14 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2022
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT04481802
Start Date
July 14 2021
End Date
October 1 2022
Last Update
July 21 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assuta
Tel Aviv, Tel Aviv, Israel